8-K filing — Imunon, Inc. (IMNN)
Filed: 2026-10-27 AccNo: 0001493152-26-048625 Size: 16 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
IMUNON To Discuss OVATION 1 Clinical Study At Its Sept. 23 R&D Day
IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced the agenda and speaker lineup for its upcoming R&D Day highlighting IMNN-001, the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Imunon Enters Agreement to Sell ThermoDox® Rights to VoxelDox Therapeutics
Imunon, Inc. has announced an agreement to divest its rights to ThermoDox®, a heat-activated liposomal formulation of doxorubicin, to VoxelDox Therapeutics, Inc.
IMUNON Sells ThermoDox Rights To VoxelDox; IMUNON Receive Equity Ownership Stake In VoxelDox With Payments Of Up To $16.5M Contingent On Meeting Development Milestones And Royalties
Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma TrialSale Reinforces IMUNON's Commitment to Its
Imunon Announces Exchange Of $1.2M Debt For Non-Convertible Series B Preferred Stock